跳至主要内容
临床试验/KCT0006784
KCT0006784招募中未知

Effects of Bojungikgi-tang on anorexic patients with atopic dermatitis: a protocol for a randomized, usual care-controlled, assessor-blinded, parallel, pilot clinical trial

Daejeon Korean Medicine Hospital of Daejeon University0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
19?(Year) 至 65?(Year)(—)
性别
All

入选标准

  • (1) adults aged 19-65 years at the screening visit
  • (2) the intensity of anorexia measured by 0-100mm visual analogue scale is 40 points or more
  • (3) diagnosis of atopic dermatitis based on the Hanifin and Rajka diagnostic criteria
  • (4) mild to moderate atopic dermatitis diagnosed by the SCORing of Atopic Dermatitis score (score 15–50).
  • (5) those who have voluntarily signed written informed consent approved by the institutional review board, after sufficient explanation of this study

排除标准

  • (1) those who have an organic disease that can cause anorexia or have alarm symptoms such as rapid weight loss of 10% or more within the last 6 months
  • (2) those who have received an appetite stimulant, health functional food (other than lactic acid bacteria) and Korean medicine treatment for the purpose of improving anorexia within 2 weeks prior to screening
  • (3) those with severe skin diseases other than atopic dermatitis
  • (4) those who have received oral steroids, oral antibiotics, systemic immunosuppressants, or systemic photochemotherapy within 4 weeks prior to screening, those who have used antihistamines, topical steroids, topical immunomodulators and topical antibiotics within 1 week prior to screening, and those who received health functional food (excluding lactic acid bacteria) and Korean medicine treatment for the purpose of improving atopic dermatitis within 2 weeks prior to screening
  • (5) those who started administering lactic acid bacteria within 2 weeks prior to screening
  • (6) participants with serious medical conditions to participate in this clinical trial
  • 6-1. those who have been diagnosed with a mental illness such as anorexia nervosa, depression, or anxiety disorder
  • 6-2. uncontrolled hypertension (in case of systolic blood pressure of 180 mmHg or higher or diastolic blood pressure of 110 mmHg or higher at screening)
  • 6-3. uncontrolled diabetes (in case of HbA1c of 9% or higher or fasting blood glucose of 160 mg/dl or higher at screening)
  • 6-4. severe liver or renal disease (aspartate aminotransferase or alanine aminotransferase levels = 3 times upper limit of normal or creatinine levels = 2 times upper limit of normal)
  • 6-5. past or present malignancy
  • 6-6. serious uncontrolled systemic diseases including cardiovascular, respiratory, digestive, genitourinary, nervous/psychiatric and blood diseases, or serious infectious diseases
  • (7) participants with a history of alcohol abuse or drug abuse within the past year
  • (8) participants with genetic problems, such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
  • (9) participants with known hypersensitivity to investigational products
  • (10) participants who had taken other investigational products within 4 weeks
  • (11) women who are pregnant or lactating, or women who do not agree to use effective methods of contraception during the clinical trial
  • (12) participants who are judged to be inappropriate for participating this study

研究者

发起方
Daejeon Korean Medicine Hospital of Daejeon University

相似试验